Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
Authors:
- Gillian MooreGMGillian Moore
- Clara LightnerCLClara Lightner
- Samira ElbaiSESamira Elbai
- Lauren BradyLBLauren Brady
- Siobhan NicholsonSNSiobhan Nicholson
- Ronan RyanRRRonan Ryan
- Katie E. O’sullivanKOKatie E. O’sullivan
- Kenneth J. O’byrneKOKenneth J. O’byrne
- Carmen Blanco-AparicioCBCarmen Blanco-Aparicio
- Sinead CuffeSCSinead Cuffe
- Michael O’neillMOMichael O’neill
- Susan HeaveySHSusan Heavey
Open Access
Abstract
PIM kinases are constitutively active proto-oncogenic serine/threonine kinases that play a role in cell cycle progression, metabolism, inflammation and drug resistance. PIM kinases interact with and stabilize p53, c-Myc and parallel signaling pathway PI3K/Akt. This study evaluated PIM kinase expression in NSCLC and in response to PI3K/mTOR inhibition. It investigated a novel preclinical PI3K/mTOR/PIM inhibitor (IBL-301) in vitro and in patient-derived NSCLC tumor tissues. Western blot analysis confirmed PIM1, PIM2 and PIM3 are expressed in NSCLC cell lines and PIM1 is a marker of poor prognosis in patients with NSCLC. IBL-301 decreased PIM1, c-Myc, pBAD and p4EBP1 (Thr37/46) and peIF4B (S406) protein levels in-vitro and MAP kinase, PI3K-Akt and JAK/STAT pathways in tumor tissue explants. IBL-301 significantly decreased secreted pro-inflammatory cytokine MCP-1. Altered mRNA expression, including activated PIM kinase and c-Myc, was identified in Apitolisib resistant cells (H1975GR) by an IL-6/STAT3 pathway array and validated by Western blot. H1975GR cells were more sensitive to IBL-301 than parent cells. A miRNA array identified a dysregulated miRNA signature of PI3K/mTOR drug resistance consisting of regulators of PIM kinase and c-Myc (miR17-5p, miR19b-3p, miR20a-5p, miR15b-5p, miR203a, miR-206). Our data provides a rationale for co-targeting PIM kinase and PI3K-mTOR to improve therapeutic response in NSCLC.Keywords
Funding Information
- Enterprise Ireland (IP20150366E)
This publication has 74 references indexed in Scilit:
- Suppression of Induced microRNA-15b Prevents Rapid Loss of Cardiac Function in a Dicer Depleted Model of Cardiac DysfunctionPLOS ONE, 2013
- Analysis of Transcriptional Regulation of the Human miR-17-92 Cluster; Evidence for Involvement of Pim-1International Journal of Molecular Sciences, 2013
- MicroRNA-16 Is Down-Regulated in Mutated FLT3 Expressing Murine Myeloid FDC-P1 Cells and Interacts with Pim-1PLOS ONE, 2012
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer CellsCancer Cell, 2012
- Expression of Truncated Eukaryotic Initiation Factor 3e (eIF3e) Resulting from Integration of Mouse Mammary Tumor Virus (MMTV) Causes a Shift from Cap-dependent to Cap-independent TranslationJournal of Biological Chemistry, 2011
- Monocyte Chemoattractant Protein–1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8+ CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activityBMC Cancer, 2010
- Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinomaOncogene, 2010
- Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1Oncogene, 2001
- Delineation of prognostic biomarkers in prostate cancerNature, 2001